A putative class action charges Wyeth Inc. with violating antitrust and consumer protection laws by impeding the introduction of a generic version of its antidepressant Effexor XR.
The suit, filed Oct. 21 on behalf of indirect purchasers of Effexor XR, alleges Wyeth fraudulently obtained three patents on Effexor XR, then sued 13 generic drug makers that sought approval to produce the drug, so it could postpone the rollout of their versions by two years.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
